NCT01229839CompletedPhase 3
Chemoembolization of Unresectable Hepatocellular Carcinoma With or Without Mixing the Chemotherapy With Lipiodol: Effectiveness and Safety. A Prospective and Randomized Clinical Trial.
Sun Yat-sen University1 site in 1 country668 target enrollmentStarted: August 1, 2013Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 668
- Locations
- 1
- Primary Endpoint
- overall survival
Study Overview
Brief Summary
TACE is considered the standard treatment for unresectable HCC on the basis of the fact that there are no alternative to curative procedures.But the optimal combined regimen is still unclear. One of the controversy is do the protocol should contain lipiodo and how to executer. The investigators hypothesize that TACE without mixing the chemotherapy with lipiodol is not unacceptably worse than TACE mixing the chemotherapy with lipiodol.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Factorial
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Eligibility criteria:
- •Inclusion Criteria:
- •Adults patients with a diagnosis of HCC which is not amenable to surgical resection ,local ablative therapy and any other cured treatment.
- •Patients must have at least one tumor lesion that can be accurately measured according to EASL criteria. And the lesion has not been previously treated with TACE, surgery, radiation therapy, radiofrequency ablation, percutaneous ethanol or acetic acid injection, or cryoablation.
- •No serious concurrent medical illness
- •Unresectable BCLC stage A-B disease
- •No cirrhosis or cirrhotic status of Child-Pugh class A
- •No significant renal impairment (creatinine clearance < 30 mL/minute) or patients on dialysis
- •No current infections requiring antibiotic therapy
- •Not on anticoagulation or suffering from a known bleeding disorder
- •No unstable coronary artery disease or recent MI
- •The following laboratory parameters:
- •Platelet count ≥ 60,000/µL
- •Hemoglobin ≥ 8.5 g/dL
- •Total bilirubin ≤ 1.5 mg/dL Serum albumin ≥ 35 g/L
- •ASL and AST ≤ 5 x upper limit of normal
- •Serum creatinine ≤ 1.5 x upper limit of normal
- •INR ≤ 1.5 or PT/APTT within normal limits
- •Absolute neutrophil count (ANC) >1,500/mm3
- •Ability to understand the protocol and to agree to and sign a written informed consent document
Exclusion Criteria
- •Known history of HIV
- •History of organ allograft
- •Pregnant or breast-feeding patients
- •Known or suspected allergy to the investigational agents or any agent given in association with this trial.
- •Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
- •Evidence of bleeding diathesis.
- •Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.
- •Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug
- •Serious non-healing wound, ulcer, or bone fracture
- •Known central nervous system tumors including metastatic brain disease
- •severe Arterioportal Shunts or Arteriavein Shunts
Arms & Interventions
infusion group
Experimental
Infusion of anticancer agent followed by Embolization
Intervention: Embolization (Other)
infusion group
Experimental
Infusion of anticancer agent followed by Embolization
Intervention: Infusion of anticancer agent (Other)
lipiodol chemotherapy group
Experimental
Infusion of mixture of anticancer agent and lipiodol followed by Embolization
Intervention: Embolization (Other)
lipiodol chemotherapy group
Experimental
Infusion of mixture of anticancer agent and lipiodol followed by Embolization
Intervention: Infusion of mixture of anticancer agent and lipiodol (Other)
Outcomes
Primary Outcomes
overall survival
Time Frame: 3 year
Secondary Outcomes
- Time to progression(3 year)
Investigators
Shi Ming
Professor
Sun Yat-sen University
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 4
Traditional (Traditional Chemoembolization) TACE Versus Microsphere TACECarcinoma, HepatocellularNCT00936689Rita Golfieri178
Recruiting
Not Applicable
TACE-HAIC vs. HAIC for Potentially Resectable HCCPotentially ResectionHepatocellular CarcinomaNCT03591705Sun Yat-sen University240
Completed
Phase 1
Chemoembolization of Non-resectable Non-metastatic Hepatocellular Carcinoma Using Embolization MicrospheresLocalized Non-Resectable Adult Hepatocellular CarcinomaNCT02870010Centre Hospitalier Universitaire Dijon21
Unknown
Phase 3
Adjuvant Therapies for Patients With HCC and MVIHepatocellular CarcinomaNCT02436902Guangxi Medical University240
Recruiting
Phase 3
Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver CarcinomaHepatocellular CarcinomaNCT03895359London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's128